29 Recruiting Epithelial Ovarian Cancer Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Epithelial Ovarian Cancer
Related Conditions
Top Recruiting Epithelial Ovarian Cancer Studies
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
📍 Arizona Oncology Associates, PC - HAL — Phoenix, Arizona
View Study & Checklist ➔Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
View Study & Checklist ➔Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
📍 Los Angeles Hematology Oncology Medical Group — Glendale, California
View Study & Checklist ➔T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
📍 Fred Hutch Cancer Center — Seattle, Washington
View Study & Checklist ➔CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
📍 University of Tennessee Medical Center - Knoxville — Knoxville, Tennessee
View Study & Checklist ➔A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
📍 University of Alabama at Birmingham (UAB) Hospital /ID# 274793 — Birmingham, Alabama
View Study & Checklist ➔Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
📍 Advent Health — Orlando, Florida
View Study & Checklist ➔AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
📍 Research Site — Birmingham, Alabama
View Study & Checklist ➔Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
📍 Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔